Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial
Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial. // The Lancet Microbe. – URL: https://www.sciencedirect.com/science/article/pii/S2666524726001023?dgcid=rss_sd_all
Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial. The Lancet Microbe. https://www.sciencedirect.com/science/article/pii/S2666524726001023?dgcid=rss_sd_all
“Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial.” The Lancet Microbe.
@article{article68968,
title = {Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial},
journal = {The Lancet Microbe},
url = {https://www.sciencedirect.com/science/article/pii/S2666524726001023?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Clinical Epidemiology and Global Health, Volume 42 Author(s): Dennis Kithinji, Fausto Ciccacci, Benjamin Welu, Harrison Ndoi, Claudia Mosconi, Carolina De Santo, Mariachiara Carestia,...
Publication date: November–December 2026 Source: Clinical Epidemiology and Global Health, Volume 42 Author(s): Alex S. Borromeo, Allan M. Manaloto, Rhealeen V. Vicedo, Jessica C. Villano, Maribel F. Valencia, Walton Wider